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INTRODUCTION
Staphylococcus aureus is a leading human pathogen of 
significant clinical importance, responsible for a wide 
array of infections from superficial skin infections to 
more  serious  invasive  infections,  including  pneu-
monia, septicemia, and endocarditis. It is also one of 
the most common ophthalmic pathogens   recovered 
from  conjunctivitis  and  other  ocular  infections.1 
Since the isolation of the first methicillin-resistant S. 
aureus (MRSA) in 1961,2 the increasing prevalence of 
MRSA worldwide has become a growing concern,3,4 
prompting the typing of S. aureus in order to support 
infection control measures, investigate suspected out-
breaks, and evaluate nosocomial transmission.
Historically, MRSA pathogens were almost exclu-
sively isolated from hospitals or hospital-associated 
facilities.  However,  there  have  been  an  increasing 
number of MRSA cases reported in individuals with 
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ABSTRACT
Purpose: Methicillin-resistant Staphylococcus aureus (MRSA) strains are commonly classified as 
  hospital-acquired (HA) or community-acquired (CA). Typical HA-MRSA isolates are characterized 
by multidrug resistance and the SCCmec type II cassette, while CA-MRSA isolates are generally 
susceptible to more drug classes, are often of SCCmec type IV, and frequently carry the Panton-
Valentine leukocidin (PVL) genes. This study determined the presence of traits characteristic for 
CA and HA strains in ocular MRSA isolates.
Materials and Methods: Fifty-six recent ocular isolates, consisting of 40 MRSA and 16 methicillin-
susceptible Staphylococcus aureus (MSSA) comparator strains, were characterized. Minimum inhibi-
tory concentration (MIC) testing was done according to current Clinical and Laboratory Standards 
Institute guidelines. Detection of the PVL encoding genes and determination of the SCCmec type 
was done by polymerase chain reaction (PCR), while spa typing and cluster analysis was performed 
following DNA sequencing.
Results: Of the 38 typeable MRSA isolates, 22 were of SCCmec type II and 16 were of SCCmec type 
IV. All SCCmec type II isolates were multidrug-resistant, lacked the PVL genes, and were of spa type 
t002 or closely related spa types. In contrast, the SCCmec type IV isolates were resistant to fewer 
classes of antimicrobial agents, often possessed the PVL genes (75.0%), and were of spa type t008 
or closely related spa types.
Conclusions: While the majority of ocular MRSA strains in this study fit the classical profile of HA- 
and CA-MRSA, some CA-MRSA isolates exhibited higher levels of antimicrobial resistance, which 
should be of particular concern to eye-care professionals. Furthermore, the apparent association 
of spa types and SCCmec types observed here warrants further investigation and suggests that spa 
typing may be useful in future HA- and CA-MRSA characterization studies.
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no known risk factors for MRSA colonization, such 
as  admission  to  a  hospital,  surgery,  contact  with  a 
MRSA-colonized  patient,  intravenous  drug  use,  or 
previous antibiotic exposure.5–7 These isolates, termed 
  community-acquired MRSA (CA-MRSA), have become 
a global concern and have been found worldwide not 
only in the community setting but also in healthcare 
facilities.8  In  fact,  some  hospitals  have  reported  a 
predominance  of  CA-MRSA  isolates  over  hospital-
acquired  MRSA  (HA-MRSA)  isolates.9,10  Although 
the  term  “acquired”  implies  that  the  location  of 
transmission is known, the HA- and CA-designations 
have also been used to describe the phenotypic and 
molecular traits of MRSA isolates, as we have done in 
this study.
HA-MRSA  strains,  exemplified  by  the  USA100 
clone, are typically associated with nosocomial infec-
tions  including  bacteremia,11  whereas  CA-MRSA 
strains, exemplified by the USA300 clone, have been 
more commonly associated with skin and soft tissue 
infections.9,12,13 The two groups are also distinguished 
by differences in their susceptibilities to antimicrobial 
agents, the composition of the gene cassette coding for 
methicillin  resistance,  and  associated  exotoxin  pro-
files. Because CA-MRSA and HA-MRSA isolates are 
different with respect to virulence and antimicrobial 
susceptibility profiles, this information could be useful 
in the design of future strategies to prevent and treat 
ocular infections.
In contrast to HA-MRSA, which generally possess 
multiple  antimicrobial  resistance  determinants  and 
are thus multidrug-resistant, CA-MRSA are typically 
susceptible to non–β-lactam antibiotics.14 Resistance to 
β-lactam antibiotics, including methicillin, is conferred 
by a low affinity penicillin-binding protein (PBP) 2a, 
encoded by the mecA gene. The mecA gene is found 
on a mobile genetic element known as the “staphy-
lococcal cassette chromosome mec” (SCCmec).15–17 To 
date, eight major variants of SCCmec (type I to VIII) 
have been identified,18 with SCCmec type II and type 
IV found predominantly in HA-MRSA and CA-MRSA, 
respectively.19–21 The Panton-Valentine leukocidin (PVL) 
genes, coding for a pore-forming cytotoxin known to 
cause tissue necrosis and leukocyte destruction, are fre-
quently present in CA-MRSA and have been shown to 
be stable markers of CA-MRSA cases worldwide.20,22–24 
In fact, CA-MRSA has been shown to be more virulent 
compared to HA-MRSA due to the presence of various 
virulence factors, such as PVL.4,17,25,26 Both SCCmec typ-
ing and detection of the PVL locus are useful tools for 
the molecular characterization of HA- and CA-MRSA 
isolates.
A different tool used for the typing of both MRSA 
and  MSSA  is  single  locus  DNA  sequencing  of  the 
S. aureus Protein A gene variable repeat region (spa 
typing). The spa gene contains a hypervariable region 
that differs in the number of repeats (1 to 23) and the 
number of base pairs (21 to 30) in each repeat (http://
spaserver.ridom.de, accessed 20 Jul 2010).27,28 The nucle-
otide composition of each distinct repeat is determined 
and subsequently given a spa type designation based 
on the unique succession of repeats. To date, pulsed-
field gel electrophoresis (PFGE) is frequently used to 
determine clonal relationships between bacterial iso-
lates. However, the method is cumbersome and PFGE 
results  cannot  be  easily  compared  among  multiple 
laboratories.29 In contrast, the spa typing method, along 
with the recently described spa grouping algorithm 
BURP (Based Upon Repeat Patterns), provides a rapid 
and accurate method to determine clonal relationships 
among S. aureus strains.29–31
While much attention has been paid to MRSA iso-
lates from skin, soft tissue, and invasive infections, 
less is known about the prevalence and epidemiology 
of MRSA in infections of the eye. Since commensal 
bacteria from the skin and nasopharynx are often the 
source of ocular infections and CA-MRSA often cause 
skin and soft tissue infections, it was of interest to 
determine whether strains that have traits similar to 
those of HA-MRSA or those of CA-MRSA are more 
prevalent among drug-resistant isolates from ocular 
infections. As part of an ongoing study to character-
ize fluoroquinolone (FQ) resistance in ocular S. aureus 
isolates, we chose to further characterize such isolates 
with  respect  to  the  microbiological  and  molecular 
features of CA- and HA-MRSA isolated in the USA. 
Accordingly, SCCmec typing, the presence of the PVL 
gene,  and  antimicrobial  susceptibility  testing  were 
used to characterize these strains for traits typical of 
either CA-MRSA or HA-MRSA. Spa typing was also 
performed to explore its use as a potential method for 
characterizing HA-MRSA and CA-MRSA strains.
MATERIALS AND METHODS
Bacterial Strains and Growth Conditions
As part of a separate study to characterize the molecu-
lar basis of high-level FQ resistance among staphylo-
cocci, a total of 56 ocular S. aureus strains including 
MRSA  and  MSSA  were  obtained  from  Eurofins 
Medinet  (Chantilly,  Virginia,  USA).  Ocular  isolates 
were collected between 2006 and 2008, representing 
24 hospitals from 14 different U.S. states. Strains were 
isolated  from  one  of  four  different  ocular  sources 
(aqueous fluid, vitreous fluid, conjunctiva, or cornea) 
from patients aged < 1 to 90 years (61% female). Care 
was taken to ensure that no duplicate isolates were 
included in this study.96    C. K. Hesje et al.
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All strains were grown for 18–24 hr at 37°C under 
ambient conditions. For genomic DNA extractions, bac-
teria were grown in Tryptic Soy Broth (Difco, Sparks, 
Maryland).  Susceptibility  testing  was  performed 
with  Mueller-Hinton  Broth  II  (Difco).  ATCC  29213 
(American Type Culture Collection [ATCC], Manassas, 
Virginia, USA) was the S. aureus quality control strain 
used for Clinical Laboratory and Standards Institute 
(CLSI) compliant susceptibility testing.32 Two MRSA 
strains, USA300 and USA600 (ATCC), were used as 
controls for SCCmec typing.
Antimicrobial Susceptibility Testing
In  vitro  antimicrobial  susceptibility  testing  for 
besifloxacin  (BES),  moxifloxacin  (MXF),  gatifloxa-
cin (GAT), ciprofloxacin (CIP), levofloxacin (LVX), 
azithromycin  (AZI),  vancomycin  (VAN),  rifampin 
(RIF),  clindamycin  (CLI),  tobramycin  (TOB), 
erythromycin  (ERY),  tetracycline  (TET),  linezolid 
(LIN), and oxacillin (OXA) was performed accord-
ing to CLSI guidelines.32 All agents were obtained 
in powder form  from LKT Laboratories  (St. Paul, 
Minnesota, USA), with the exception of BES, which 
was obtained from Bausch & Lomb Inc. (Rochester, 
New York, USA). In accordance with the manufac-
turer’s recommendations, all agents were solubilized 
and diluted. The minimum inhibitory concentration 
(MIC)  was  reported  as  the  lowest  antimicrobial 
concentration  that  inhibited  the  visible  growth  of 
bacteria. Since susceptibility test interpretive crite-
ria (breakpoints) have yet to be defined by the Food 
and Drug Administration (FDA) or CLSI for topical 
agents, systemic breakpoints were used, where avail-
able, to classify bacterial isolates as susceptible or 
resistant. Because besifloxacin was developed as an 
exclusively topical ophthalmic agent, no breakpoints 
are currently defined.
spa Typing and BURP Cluster Analysis
Genomic  DNA  was  extracted  from  pure  bacterial 
cultures using the Wizard Genomic DNA Purification 
Kit (Promega, Madison, Wisconsin, USA) according 
to the manufacturer’s instructions and was used as 
the  template  for  polymerase  chain  reaction  (PCR) 
amplification.  The  spa  variable  repeat  region  from 
each  isolate  was  amplified  using  previously  pub-
lished  oligonucleotide  primers.33  PCR  was  carried 
out in a MyCycler thermal cycler (BioRad, Hercules, 
California, USA) in a 100 μl volume containing 0.4 μM 
primers  (Integrated  DNA  Technologies,  Coralville, 
Iowa, USA), 200 μM deoxynucleoside triphosphates 
(Omega Bio-Tek, Norcross, Georgia, USA), 1 U of Vent 
DNA polymerase and its reaction buffer containing 
2 mM  magnesium  sulfate  (New  England  Biolabs, 
Ipswich,  Massachusetts,  USA).  The  initial  cycle  of 
denaturation  (15 min  at  94°C)  preceded  30  cycles 
consisting of 0.5 min of denaturation at 94°C, 1 min 
of annealing at 59°C, and 1 min of elongation at 72°C, 
and was followed by a final cycle of elongation (10 min 
at 72°C). PCR products were purified using the EZNA 
Cycle Pure Kit (Omega Bio-Tek), and sequenced by 
ACGT Inc. (Wheeling, Illinois, USA). Clone Manager 
9 (Sci-Ed Software, Cary, North Carolina, USA) was 
used for sequence analyses, and spa types were deter-
mined  using  the  website  (http://spaserver.ridom.
de/)  developed  by  Ridom  GmbH  and  curated  by 
SeqNet.org (http://SeqNet.org/).28 The BURP clus-
tering tool in the Ridom StaphType 2.0.3 software 
package (Ridom GmbH, Würzburg, Germany) was 
used for spa type aligning and clustering.31
Detection of Genes Encoding PVL
Genomic DNA was extracted as described above and 
used as the template for PCR amplification. A 945-bp 
region  of  the  Panton-Valentine  leukocidin  genes 
(lukF-PV and lukS-PV) from each isolate was amplified 
using the oligonucleotide primers, lukS 5′-CCC ATT 
AGT ACA CAG TGG TTT CAA TC-3′ and lukF 5′-GTC 
CAG CAT TTA AGT TGC TTT GTC-3′. The primer 
sequences were designed from the published S. aureus 
strain  USA300  (GenBank  accession  no.  NC_007793) 
using  Clone  Manager  9  analysis  software  (Sci-Ed 
Software). PCR was carried out as described above in a 
25 μl volume. The initial cycle of denaturation (10 min 
at 94°C) preceded 33 cycles consisting of 0.5 min of 
denaturation  at  94°C,  0.5 min  of  annealing  at  57°C, 
and 1 min of elongation at 72°C, and was followed by 
a final cycle of elongation (10 min at 72°C).
SCCmec Typing
Genomic DNA was extracted as described by Zhang 
et al.34 with modifications. Briefly, five to ten bacterial 
colonies were suspended in 50 µl of nuclease-free water 
(Promega) and heated at 99°C for 10 min. After cen-
trifugation at 21,000 × g for 1 min, 2.5–9 µl of the super-
natant was used as the template for PCR amplification. 
The SCCmec typing assay contained eight unique and 
specific pairs of primers as previously described35 for 
SCCmec types and subtypes I, II, III, IVa, IVb, IVc, IVd, 
and V. PCR was carried out as simplex reactions using 
conditions identical to those described above for PVL 
detection.Virulence and Drug Resistance in Ocular MRSA    97
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Gel Electrophoresis
PCR  amplicons  were  visualized  using  a  UV  light 
box after electrophoresis on 1% (spa typing) or 2% 
(detection of PVL genes and SCCmec typing) agarose 
gels containing 0.1 µg/ml ethidium bromide (Omega 
Bio-Tek).
RESULTS
Published CLSI breakpoints for OXA36 were used to 
classify all ocular S. aureus isolates as either MSSA 
(n = 16) or MRSA (n = 40). With the exception of two 
MRSA isolates, where the SCCmec type could not be 
determined,  the  remaining  38  MRSA  isolates  were 
classified as either SCCmec type II (n = 22) or type IV 
(n = 16) (Table 1). Two different subtypes of the SCCmec 
type IV cassette were found with subtype IVa identi-
fied in 15 (93.8%) of the type IV isolates and subtype 
IVb being found in a single isolate (6.3%). The PVL 
genes were absent in all SCCmec type II isolates, while 
75.0% (12/16) of SCCmec type IV and 18.8% (3/16) 
of the MSSA isolates contained the PVL genes. Four 
different,  but  related,  spa  types  were  found  among 
SCCmec type II isolates while five different, but related, 
spa types were found among SCCmec type IV isolates; 
MSSA was the most diverse with respect to spa type 
with 12 different types being observed.
Susceptibility testing was performed with 14 anti-
microbial agents representing the following nine drug 
classes:  fluoroquinolones  (FQs),  macrolides,  lincos-
amides,  aminoglycosides,  tetracyclines,  rifamycins, 
glycopeptides,  oxazolidinones,  and  β-lactams.  All 
SCCmec type II isolates were resistant to at least three 
drug classes, with one isolate in this group exhibiting 
resistance  to  six  different  drug  classes.  Conversely, 
62.5% of SCCmec type IV isolates were resistant to at 
least three drug classes, with no isolate in this group 
possessing resistance to more than four different drug 
classes.
The  MIC50,  MIC90,  and  MIC  range  values  for  all 
antimicrobial agents tested are presented in Table 2. 
One hundred percent of all S. aureus isolates were sus-
ceptible to the systemic (i.e., non-ophthalmic) agents 
RIF, VAN, and LIN. Additionally, 100% of the SCCmec 
type IV isolates were susceptible to CLI and TET while 
87.5% and 93.8% of MSSA isolates and 54.5% and 95.5% 
of the SCCmec type II isolates were susceptible to these 
drugs, respectively. With the exception of BES, where 
the percentage of susceptible isolates cannot be deter-
mined due to the lack of any established resistance 
breakpoints for exclusively topical agents, all SCCmec 
type II isolates were resistant to the FQs (MXF, GAT, 
CIP, and LVX) and macrolides (AZI and ERY) tested. 
However, 37.5% and 6.3% of SCCmec type IV isolates 
were  susceptible  to  all  FQs  and  macrolides  tested, 
respectively; 56.3% of MSSA isolates were susceptible 
to the macrolides and early generation FQs (CIP and 
LVX), while 62.5% of MSSA isolates were susceptible 
to the subsequent generation of FQ agents (GAT and 
MXF). While only 13.6% of SCCmec type II isolates were 
susceptible to TOB, 93.8% of SCCmec type IV isolates 
and 81.3% of MSSA isolates exhibited susceptibility to 
this aminoglycoside.
Rifampin was the most potent antimicrobial agent 
tested  for  all  S.  aureus  isolates  with  MIC90  values 
of  0.008  µg/ml. Among  the  FQ  agents  tested,  BES 
TABLE 1  Summary of ocular S. aureus characteristics.
 
MRSA
MSSA Type II Type IV
Number of isolates 22 16 16
Source of isolates by state  
(number of sites)
AL (2), FL (1), GA (1), ID (1),  
MA (2), MD (1), MI (3), NY (2),  
OH (2), PA (4), SC (1), TN (2)
FL (1), GA (1), ID (1),  
MA (1), MD (4), MI (1),  
NC (1), NY (2), OH (4)
AL (1), FL (2), GA (1), MA (2), 
MD (1), MI (1), MO (1),  
NY (3), OH (2), PA (2)
SCCmec type (n) II (22) IVa (15) NA
IVb (1)
PVL positive, n (%) 0 (0.0%) 12 (75.0%) 3 (18.8%)
Number of spa types 4 5 12
% Resistant to 1+ drug classa 100.0% 100.0% 62.5%
% Resistant to 2+ drug classes 100.0% 93.8% 37.5%
% Resistant to 3+ drug classes 100.0% 62.5% 18.8%
% Resistant to 4+ drug classes 95.5% 6.3% 6.3%
% Resistant to 5+ drug classes 36.4% 0.0% 0.0%
% Resistant to 6+ drug classes 4.5% 0.0% 0.0%
% Resistant to 7+ drug classes 0.0% 0.0% 0.0%
aDrug classes tested included fluoroquinolones, macrolides, lincosamides, aminoglycosides, tetracyclines, rifamycins, 
glycopeptides, oxazolidinones, β-lactams.98    C. K. Hesje et al.
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was  the  most  potent  agent,  with  MIC90  values  of   
4 μg/ml for SCCmec type II and MSSA isolates and 
0.5 μg/ml  for  SCCmec  type  IV  isolates.  For  all  FQ 
agents tested, the MSSA isolates displayed the broadest 
MIC ranges. The highest MIC90 values observed among 
the SCCmec type II isolates and MSSA isolates were 
512 μg/ml for LVX, > 256 μg/ml for AZI, ERY, and 
CLI, and 256 μg/ml for TOB and CIP. In contrast the 
highest MIC90 values for SCCmec type IV isolates were   
128 μg/ml for AZI, 64 μg/ml for ERY, and 32 μg/ml 
for CIP.
The spa typing data presented in Table 3 revealed 
that all 22 SCCmec type II isolates, representing four 
different spa types, occurred within the same BURP 
cluster (spa-CC002) with spa type t002 observed most 
frequently (81.8%; 18/22). Similarly, the 16 SCCmec 
TABLE 2  Antimicrobial susceptibilities of ocular S. aureus, including 16 MSSA, 22 MRSA SCCmec type II, and 16 MRSA SCCmec 
type IV isolates.
Agent Organism
MIC (μg/ml)
% Susceptible Range 50% 90%
Besifloxacin MSSA 0.016–4 0.03 4 NAa
MRSA (type II) 0.5–8 4 4 NAa
MRSA (type IV) 0.016–1 0.25 0.5 NAa
Moxifloxacin MSSA 0.03–64 0.06 32 62.5
MRSA (type II) 2–64 32 64 0
MRSA (type IV) 0.016–2 2 2 37.5
Gatifloxacin MSSA 0.06–64 0.125 32 62.5
MRSA (type II) 2–128 64 128 0
MRSA (type IV) 0.031–2 2 2 37.5
Ciprofloxacin MSSA 0.125–256 0.5 256 56.3
MRSA (type II) 32–256 256 256 0
MRSA (type IV) 0.125–64 16 32 37.5
Levofloxacin MSSA 0.125–512 0.25 512 56.3
MRSA (type II) 8–1024 512 512 0
MRSA (type IV) 0.125–8 4 8 37.5
Azithromycin MSSA 0.5–> 256 0.5 > 256 56.3
MRSA (type II) > 256 > 256 > 256 0
MRSA (type IV) 0.5–> 256 128 128 6.3
Erythromycin MSSA 0.25–> 256 0.5 > 256 56.3
MRSA (type II) > 256 > 256 > 256 0
MRSA (type IV) 0.25–64 64 64 6.3
Clindamycin MSSA 0.063–> 256 0.125 > 256 87.5
MRSA (type II) 0.063–> 256 0.25 > 256 54.5
MRSA (type IV) 0.063–0.125 0.063 0.063 100
Tobramycin MSSA 0.25–256 0.5 256 81.3
MRSA (type II) 0.5–256 256 256 13.6
MRSA (type IV) 0.5–32 1 2 93.8
Tetracycline MSSA 0.5–32 0.5 4 93.8
MRSA (type II) 0.25–64 0.5 0.5 95.5
MRSA (type IV) 0.25–0.5 0.5 0.5 100
Rifampin MSSA 0.002–0.016 0.008 0.008 100
MRSA (type II) 0.004–0.125 0.008 0.008 100
MRSA (type IV) 0.004–0.008 0.004 0.008 100
Vancomycin MSSA 1 1 1 100
MRSA (type II) 1 1 1 100
MRSA (type IV) 0.5–1 1 1 100
Linezolid MSSA 2–4 2 4 100
MRSA (type II) 2–4 4 4 100
MRSA (type IV) 2 2 2 100
Oxacillin MSSA 0.25–0.5 0.25 0.5 100
MRSA (type II) > 8 > 8 > 8 0
MRSA (type IV) 4–> 8 > 8 > 8 0
aSince besifloxacin was developed as an exclusively topical ophthalmic agent, no breakpoints exist.Virulence and Drug Resistance in Ocular MRSA    99
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type IV isolates, representing five different spa types, 
occurred within the same BURP cluster (spa-CC008) 
with spa type t008 observed most frequently (75.0%; 
12/16). In contrast, the 16 MSSA isolates displayed 
by far the most diversity in terms of the number of 
different spa types found; with the exception of spa 
type t002, which occurred five times, no other type 
was represented more than once. The 12 different spa 
types found among the MSSA isolates comprised four 
BURP clusters (spa-CC002, spa-CC008, spa-CC084, and 
spa-CC240/773) in addition to three singletons.
DISCUSSION
Molecular and microbiological characterizations were 
conducted to determine whether ocular isolates have 
traits characteristic for CA-MRSA or HA-MRSA. To 
our knowledge, no SCCmec typing study13 has been 
conducted on an exclusively ocular set of MRSA iso-
lates. Because these isolates were also part of separate 
FQ resistance characterization studies among ocular 
isolates, a substantial fraction of strains tested here 
(41/56) had elevated FQ MIC values and therefore 
may not be fully representative of ocular MRSA in gen-
eral. Nevertheless, because most ocular infections are 
treated empirically this report of multidrug-resistant 
strains isolated from the eye with genetic traits of both 
CA-MRSA and HA-MRSA should be of interest to the 
ophthalmic community.
The results of the current study showed that all 
38  typeable  ocular  MRSA  isolates  tested  could  be 
classified as either SCCmec type II or SCCmec type 
IV, the predominant cassette types of HA-MRSA and 
CA-MRSA,  respectively.21,37  Consistent  with  previ-
ous reports,38 all the ocular SCCmec type II strains 
examined here exhibited traits typical for HA-MRSA, 
including the absence of the PVL toxin and resistance 
to multiple drug classes (Table 1). Over 95% of the 
SCCmec type II isolates were resistant to at least four 
different classes of antimicrobial agents and MIC50 
and MIC90 values against such agents were elevated 
in comparison to values observed among the SCCmec 
type  IV  isolates.  The  increased  resistance  to  non 
β-lactam antibacterials found in the SCCmec type II 
isolates may be partly due to the fact that these cas-
settes contain a variety of additional drug resistance 
gene  elements  not  found  within  SCCmec  type  IV 
cassettes.39
CA-MRSA  isolates  have  usually  been  defined  as 
containing SCCmec type IV cassettes, expressing PVL, 
and exhibiting susceptibility to non-β-lactam antimi-
crobial agents.21,40 In this study, 16 MRSA isolates were 
characterized as SCCmec type IV isolates and of these 
75% were found to contain the PVL genes. In contrast 
to the SCCmec type II isolates, which all showed high 
level  resistance  to  several  classes  of  antimicrobial 
agents, all SCCmec type IV isolates shared only resis-
tance to β-lactam agents. There were, however, high 
levels  of  resistance  to  other  drug  classes  observed; 
among the SCCmec type IV isolates, susceptibility to 
the FQ and macrolide classes was only 37.5% and 6.3%, 
respectively.
Recently, in a large MRSA surveillance study con-
ducted in San Francisco, Diep et al. found that almost 
90% of their USA300 strains (n = 188) were resistant to 
ERY, over 60% were resistant to CIP, over 24% were 
resistant to TET, and over 10% were resistant to CLI.41 
These data, taken together with our resistance data, 
indicate  that  resistance  to  non-β-lactam  antibiotics 
might be increasing among SCCmec type IV isolates. 
The increased resistance and the fact that 25% of our 
SCCmec type IV isolates did not produce PVL, sug-
gest that the criteria for classifying a MRSA isolate as 
either CA- or HA-MRSA are blurring. Nonetheless, the 
MIC90 values for all antimicrobial agents were equal to 
TABLE 3  spa clusters, spa types, repeat patterns, and (n) 
number for ocular S. aureus.
MRSA SCCmec type II (n=22)
spa CC002 cluster  
t002 26-23-17–34-17–20-17-12–17-16 (18)
t045 26-17–20-17-12-17-16 (1)
t067 26-23-17–34-17–20-17-12-17 (2)
t242 26-23-17-13-17-20-17-12-17-16 (1)
 MRSA SCCmec type IV (n=16)
spa CC008 cluster
t008 11–19-12–21-17–34-24–34-22–25 (12)
t024 11–12–21-17–34-24–34-22–25 (1)
t334 11–12–21-17–34-22–25 (1)
t622 11–19-12–21-17–34-22–25 (1)
t1578 11–19-12-21-17–34-24–34-17 (1)
MSSA (n=16)
spa CC002 cluster
t002 26-23-17–34-17–20-17-12-17-16 (5)
t242 26-23-17-13–17–20-17-12-17-16 (1)
spa CC008 cluster
t008 11–19-12-21-17-34-24–34-22-25 (1)
t064 11–19-12-05-17-34-24-34-22-25 (1)
spa CC084 cluster
t084 07-23-12–34–34-12–12–23-02-12–23 (1)
t346 07-23-12-34-12-12–23-02-12–23 (1)
t491 26-23-12-34-34-12-12–23-02-12-23 (1)
spa CC240/773 cluster
t240 04-44-33-31-12-16–34-16-12-22–34 (1)
t773 04-44-33-31-16-12–25-22–34 (1)
Singletons
t004 09-02-16-13-13-17-34-16-34 (1)
t005 26-23-13–23-31-05-17–25-17–25-16–28 (1)
t160 07-23-21-24–33-22-17 (1)100    C. K. Hesje et al.
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or lower for SCCmec type IV isolates than for SCCmec 
type II isolates.
PFGE or spa typing can reveal clonal relationships 
among MRSA isolates. The most observed types in 
this study were spa types t008 and t002 represent-
ing  the  clones  USA300  and  USA100,  respectively. 
These  spa  types  have  been  frequently  reported  as 
common spa types found in large surveillance stud-
ies worldwide.42–44 In the relative global frequencies 
database on the Ridom SpaServer website, spa types 
t003  (12.5%),  t032  (10.7%),  t008  (6.6%),  and  t002 
(5.9%) are listed as the most commonly isolated spa 
types (http://spaserver.ridom.de/frequencies.shtml, 
accessed 07 Jun 2010). Although the Ridom database 
does contain isolates from all over the world, the data 
set is dominated by European isolates. For example, 
our analysis of the Ridom database revealed that of 
the 50 most frequent spa types (those with a preva-
lence of 0.25% or higher), 95.5% of the 59,811 isolates 
with country of origin listed were from Europe, while 
only 1.5% originated in the United States. The most 
common spa types among the 898 U.S. isolates were 
t008 (69.7%), t002 (11.8%), t064 (4.7%), t045 (2.8%), t024 
(2.0%), and t242 (1.6%); the same six spa types were 
also identified among the 54 ocular isolates described 
here. These data support the hypothesis that the spa 
types of ocular S. aureus are similar to those isolated 
from other body sites.
All MRSA isolates containing the SCCmec type II ele-
ment were either of spa type t002 or one of three similar 
spa types that belong to cluster spa-CC002. Type t002 
was the founder of this cluster and was, with 18 iso-
lates, the most prevalent spa type. Similarly, all strains 
containing a SCCmec type IV element were either spa 
type t008 or one of four spa types that are part of the 
spa-CC008 cluster. Type t008 was the founder of the 
spa-CC008 cluster and was, with 12 isolates, the second 
most prevalent spa type among MRSA isolates.
Spa types t002 and t242 (cluster spa-CC002) and 
t008 (cluster spa-CC008) were present in the MRSA 
and the MSSA groups. Several previous reports have 
documented the in vivo conversions of clinical MSSA 
to MRSA and vice versa.45,46 The acquisition or loss of 
DNA encoding the SCCmec cassette may occur more 
frequently in SCCmec type IV isolates than in SCCmec 
type II isolates, presumably due to the smaller, more 
mobile SCCmec type IV cassette.19,21,47 It remains to be 
determined if an ancestral strain acquired a specific 
SCCmec element and then diversified into clones with 
similar spa types, or if related strains independently 
converted from MSSA to MRSA by integrating SCCmec 
elements.48
In conclusion, the molecular characterization and, 
to some extent, the antimicrobial phenotypes of the 
MRSA isolates tested in this study demonstrate that 
SCCmec type II and SCCmec type IV isolates generally 
fit the classical definition of HA- and CA-MRSA strains, 
respectively. In contrast to MRSA, MSSA isolates were 
more diverse in their PVL, spa type, and antimicro-
bial susceptibility profiles, whereas the MRSA isolates 
were less varied with respect to these traits. In par-
ticular, the presence of a dominant spa type and the 
similarity between spa repeats among isolates with the 
same SCCmec type suggests that spa typing may be an 
additional useful tool when molecularly investigating 
and classifying ocular MRSA isolates as either CA- or 
HA-MRSA.
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